Franco Grimolizzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Franco Grimolizzi has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Beatriz Molina
Medikas Clinic, Somerset, Bristol, UK
3 shared publicationsEditta Buttura da Prato
Private practice, Verona, Italy
3 shared publicationsMaria Stoikou
Department of Biomedicine, University of Basel, University Hospital of Basel, Basel, Switzerland
3 shared publicationsOlav Lapaire
University Women's Hospital, University Hospital of Basel, Basel, Switzerland
3 shared publicationsPaul Hasler
Department of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland
3 shared publications- Sinuhe Hahn
Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland
3 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Biogerontology
- Vol. 27 (5) , 148
An aging essential 8: closing the gap between geroscience and the public it serves
- 26 August 2026
- Published by Springer Nature in Biogerontology
- Vol. 27 (5) , 148
Open AccessAn aging essential 8: closing the gap between geroscience and the public it serves
- 3 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , e465-e466
Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology
- 3 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , e465-e466
Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology
- 18 June 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (7)
Retiring M1/M2: a view from the succinate receptor
- 18 June 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (7)
Retiring M1/M2: a view from the succinate receptor
- 24 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114648
Engineered extracellular vesicles platforms: translational considerations
- 24 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114648
Engineered extracellular vesicles platforms: translational considerations
- Open Access
- 3 September 2025
- Published by Elsevier in EBioMedicine
- Vol. 119, 105908
Inflammaging links Life's Essential 8 to white-matter brain ageing
- 3 September 2025
- Published by Elsevier in EBioMedicine
- Vol. 119, 105908
Open AccessInflammaging links Life's Essential 8 to white-matter brain ageing
- Open Access
- 18 December 2024
- Published by BioExcel in Drugs in Context
- Vol. 13, 1-10
Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers
This article examines the real-world safety profile of aliaxin fillers fillers derived from worldwide post-marketing surveillance data
- 18 December 2024
- Published by BioExcel in Drugs in Context
- Vol. 13, 1-10
Open AccessGood scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers
This article examines the real-world safety profile of aliaxin fillers fillers derived from worldwide post-marketing surveillance data
- Open Access
- 12 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3216
Intradermal Injection of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan: Where Do We Stand and Where Are We Headed in Regenerative Medicine?
Hyaluronic acid (HA) is a remarkably multifaceted biomacromolecule, playing a role in regulating myriad biological processes such as wound healing, tissue regeneration, anti-inflammation, and immunomodulation. Crosslinked high- and low-molecular-weight hyaluronic acid hydrogels achieve higher molar concentrations, display slower degradation, and allow optimal tissue product diffusion, while harnessing the synergistic contribution of different-molecular-weight hyaluronans. A recent innovation in the world of hyaluronic acid synthesis is represented by NAHYCO® Hybrid Technology, a thermal process leading to hybrid cooperative hyaluronic acid complexes (HCC). This review summarizes the current literature on the in vitro studies and in vivo applications of HCC, from facial and body rejuvenation to future perspectives in skin wound healing, dermatology, and genitourinary pathologies.
- 12 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3216
Open AccessIntradermal Injection of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan: Where Do We Stand and Where Are We Headed in Regenerative Medicine?
Hyaluronic acid (HA) is a remarkably multifaceted biomacromolecule, playing a role in regulating myriad biological processes such as wound healing, tissue regeneration, anti-inflammation, and immunomodulation. Crosslinked high- and low-molecular-weight hyaluronic acid hydrogels achieve higher molar concentrations, display slower degradation, and allow optimal tissue product diffusion, while harnessing the synergistic contribution of different-molecular-weight hyaluronans. A recent innovation in the world of hyaluronic acid synthesis is represented by NAHYCO® Hybrid Technology, a thermal process leading to hybrid cooperative hyaluronic acid complexes (HCC). This review summarizes the current literature on the in vitro studies and in vivo applications of HCC, from facial and body rejuvenation to future perspectives in skin wound healing, dermatology, and genitourinary pathologies.
- Top Cited PapersOpen Access
- 5 February 2024
- Published by Springer Nature in Philosophy, Ethics, and Humanities in Medicine
- Vol. 19 (1) , 1-7
The ethical foundations of patient-centered care in aesthetic medicine
This article addresses some critical aspects of the relationship between aesthetic medicine (AM) and ethics and proposes a possible deontological ethical line to pursue based on current practices. The role of AM has always been controversial and suffers from unclear practical and moral boundaries, even within academic settings, since it aims to improve the appearance of individuals, not to cure a disease. Today, it is essential and pertinent to discuss these issues, as AM specialists are dealing with a growing and increasingly demanding patient population that has undergone profound evolution in recent years. Current challenges within the field of AM include a lack of global uniformity concerning the education of AM specialists, an increasing number of physicians practicing AM with diverse training backgrounds, the spread of AM being practiced outside of medical practice or hospital settings, and the influence of social media where the success is modelled and dictated by the identification of a youthful appearance). By the field of action enriched by technologies that aim not only at enhancement per se but also at the preservation and regeneration of tissues, it is necessary to establish an active multidisciplinary discussion on the definition of shared ethical limits. This discussion would allow AM to fully reclaim its identity as a specialty that aims to improve patient well-being whilst maintaining respect for patient aesthetic harmony, the expertise of specialists who practice AM, the essential role of safety, and awareness of the importance of a confidential doctor−patient relationship.
- 5 February 2024
- Published by Springer Nature in Philosophy, Ethics, and Humanities in Medicine
- Vol. 19 (1) , 1-7
Top Cited PapersOpen AccessThe ethical foundations of patient-centered care in aesthetic medicine
This article addresses some critical aspects of the relationship between aesthetic medicine (AM) and ethics and proposes a possible deontological ethical line to pursue based on current practices. The role of AM has always been controversial and suffers from unclear practical and moral boundaries, even within academic settings, since it aims to improve the appearance of individuals, not to cure a disease. Today, it is essential and pertinent to discuss these issues, as AM specialists are dealing with a growing and increasingly demanding patient population that has undergone profound evolution in recent years. Current challenges within the field of AM include a lack of global uniformity concerning the education of AM specialists, an increasing number of physicians practicing AM with diverse training backgrounds, the spread of AM being practiced outside of medical practice or hospital settings, and the influence of social media where the success is modelled and dictated by the identification of a youthful appearance). By the field of action enriched by technologies that aim not only at enhancement per se but also at the preservation and regeneration of tissues, it is necessary to establish an active multidisciplinary discussion on the definition of shared ethical limits. This discussion would allow AM to fully reclaim its identity as a specialty that aims to improve patient well-being whilst maintaining respect for patient aesthetic harmony, the expertise of specialists who practice AM, the essential role of safety, and awareness of the importance of a confidential doctor−patient relationship.
- Open Access
- 21 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1743
Efficacy and tolerability of Profhilo® Structura intended to restore lateral cheek fat compartment: An observational pilot study
Background and Aims: Hyaluronic acid (HA)‐based injections are used worldwide to improve skin defects associated with aging and ultraviolet light/environmental exposure. HA formulations developed according to molecular weight or with additional components, for example, cross‐linking reagents, are limited by their low biological activity and concentration limit. NAHYCO™ technology has enabled the production of hybrid cooperative complexes (HCCs) of low and high molecular weight HA. Developed for injection into the fat compartments of the face and previously demonstrating potential benefits for adipose tissue restoration, Profhilo Structura® is a new 2 mL HCC formulation comprising low molecular weight HA (45 mg/mL) and high molecular weight HA (45 mg/mL). To evaluate the efficacy and tolerability of Profhilo Structura® to restore adipose tissue compartments in the lateral cheek fat compartment.Methods: Fifty healthy enrolled subjects received two injections, 1 month apart, and were evaluated 3 months posttreatment. Investigators performed clinical evaluations (Facial Volume Loss Scale [FVLS] and Wrinkle Severity Rating Scale [WSRS]) at different time points. Subjects also completed self‐evaluation assessments following treatment.Results: A significant improvement in FVLS and WSRS clinical scores after the first treatment was observed; treatment benefit was maintained 3 months after treatment completion and confirmed by subject self‐assessment. Most participants reported an improvement, particularly a marked reduction of wrinkles and increased skin firmness. No serious adverse events were reported, confirming the excellent safety profile of HCC injectable devices.Conclusions: Overall, the study highlighted the efficacy and tolerability of the studied medical device proving its effect on adipose tissue.
- 21 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1743
Open AccessEfficacy and tolerability of Profhilo® Structura intended to restore lateral cheek fat compartment: An observational pilot study
Background and Aims: Hyaluronic acid (HA)‐based injections are used worldwide to improve skin defects associated with aging and ultraviolet light/environmental exposure. HA formulations developed according to molecular weight or with additional components, for example, cross‐linking reagents, are limited by their low biological activity and concentration limit. NAHYCO™ technology has enabled the production of hybrid cooperative complexes (HCCs) of low and high molecular weight HA. Developed for injection into the fat compartments of the face and previously demonstrating potential benefits for adipose tissue restoration, Profhilo Structura® is a new 2 mL HCC formulation comprising low molecular weight HA (45 mg/mL) and high molecular weight HA (45 mg/mL). To evaluate the efficacy and tolerability of Profhilo Structura® to restore adipose tissue compartments in the lateral cheek fat compartment.Methods: Fifty healthy enrolled subjects received two injections, 1 month apart, and were evaluated 3 months posttreatment. Investigators performed clinical evaluations (Facial Volume Loss Scale [FVLS] and Wrinkle Severity Rating Scale [WSRS]) at different time points. Subjects also completed self‐evaluation assessments following treatment.Results: A significant improvement in FVLS and WSRS clinical scores after the first treatment was observed; treatment benefit was maintained 3 months after treatment completion and confirmed by subject self‐assessment. Most participants reported an improvement, particularly a marked reduction of wrinkles and increased skin firmness. No serious adverse events were reported, confirming the excellent safety profile of HCC injectable devices.Conclusions: Overall, the study highlighted the efficacy and tolerability of the studied medical device proving its effect on adipose tissue.